Ardelyx Inc. is ranked 9th on hedge funds' list of best biotech penny stocks to buy

From Yahoo Finance: 2025-04-16 11:21:00

FDA’s Peter Marks’ departure raises concerns about review program and future FDA stability, causing investors to look for biotech names less reliant on FDA approvals.
Stifel’s Paul Matteis advises investors to focus on companies with de-risked profiles amid FDA uncertainty, highlighting short-term delays in drug approvals and the need for more selective stock selections.
Matteis notes that companies tied to commercial launches are outperforming, signaling a shift in focus away from FDA-dependent firms in the biotech sector.
Ardelyx Inc. (NASDAQ:ARDX) is ranked 9th on the list of best biotech penny stocks to buy according to hedge funds, with a focus on XPHOZAH’s growth potential and AI stocks as promising investments in a shorter timeframe.
Ardelyx Inc. (NASDAQ:ARDX) commercializes medicines like IBSRELA and XPHOZAH, generating $57.2 million in net product sales revenue in Q4 2024, with projections for $750 million in annual net sales revenue before XPHOZAH’s patent expires.
Medicare Part D coverage for XPHOZAH was eliminated in January, but Ardelyx is dedicated to ensuring patient access through education and support programs like ArdelyxAssist.

NVIDIA (NVDA) Beats Revenue Estimates, Strong Outlook